Alexander Disease

National Organization for Rare Disorders, Inc.

Skip to the navigation


It is possible that the main title of the report Alexander Disease is not the name you expected. Please check the synonyms listing to find the alternate name(s) and disorder subdivision(s) covered by this report.


  • dysmyelogenic leukodystrophy
  • dysmyelogenic leukodystrophy-megalobare
  • fibrinoid degeneration of astrocytes
  • fibrinoid leukodystrophy
  • hyaline panneuropathy
  • leukodystrophy with rosenthal fibers
  • megalencephaly with hyaline inclusion
  • megalencephaly with hyaline panneuropathy

Disorder Subdivisions

  • None

General Discussion

Alexander disease is named after the physician who first described the condition in 1949 (WS Alexander). It is an extremely rare, usually progressive and fatal, neurological disorder. Initially it was detected most often during infancy or early childhood, but as better diagnostic tools have become available has been found to occur with similar frequency at all stages of life. Alexander disease has historically been included among the leukodystrophies--diseases of the white matter of the brain. These diseases affect the fatty material (myelin) that forms an insulating wrapping (sheath) around certain nerve fibers (axons). Myelin enables the efficient transmission of nerve impulses and provides the "whitish" appearance of the so-called white matter of the brain. There is a marked deficit in myelin formation in most early onset cases of Alexander disease, and sometimes in later onset cases, particularly in the front (frontal lobes) of the brain's two hemispheres (cerebrum). However, white matter defects are sometimes not observed in later onset cases. Instead, the unifying feature among all Alexander disease cases is the presence of abnormal protein aggregates known as "Rosenthal fibers" throughout certain regions of the brain and spinal cord (central nervous system [CNS]). These aggregates occur in astrocytes, a particular cell type in the CNS that helps maintain a normal CNS environment. Accordingly, it is more appropriate to consider Alexander disease a disease of astrocytes (an astrogliopathy) than a white matter disease (leukodystrophy).


Historically, three forms of Alexander disease have been described based on age of onset, Infantile, Juvenile and Adult; but an analysis of a large number of cases concluded that the disease is better described as having two forms, Type I, which generally has an onset by age 4, and Type II, which can have onset at any age, but primarily after age 4. Each type accounts for about half of the reported cases. Symptoms associated with the Type I form include a failure to grow and gain weight at the expected rate (failure to thrive); delays in the development of certain physical, mental, and behavioral skills that are typically acquired at particular stages (psychomotor retardation); and sudden episodes of uncontrolled electrical activity in the brain (seizures). Additional features typically include progressive enlargement of the head (macrocephaly); abnormally increased muscle stiffness and restriction of movement (spasticity); lack of coordination (ataxia); and vomiting and difficulty swallowing, coughing, breathing or talking (bulbar and pseudobulbar signs). Nearly 90% of infantile patients display developmental problems and seizures, and over 50% the other symptoms mentioned; however, no single symptom or combination of symptoms is always present.

Patients with type II Alexander disease rarely show delay or regression of development, macrocephaly or seizures, and mental decline may develop slowly or not at all. Instead, about 50% display bulbar/pseudobulbar signs, about 75% have ataxia and about 33% spasticity. Because these symptoms are not specific, adult Alexander disease is sometimes confused with more common disorders such as multiple sclerosis or the presence of tumors. (For information on these diseases, see the related disorders section of this report.)

The two different forms of Alexander disease are generalizations rather than defined entities. In actuality there is an overlapping continuum of presentations; a one year old could present with symptoms more typical of a 10 years old, and vice-versa. However, in all cases the symptoms almost always worsen with time and eventually lead to death, with the downhill course generally (but not always) being swifter the earlier the onset.


About 95% of Alexander disease cases are caused by mutations in a structural protein called glial fibrillary acidic protein (GFAP) that is found almost exclusively in astrocytes. The cause of the other 5% of cases is not known.

The GFAP mutations are dominant. Dominant genetic disorders occur when only a single copy of an abnormal gene is necessary to cause a particular disease. The abnormal gene can be inherited from either parent or can be the result of a new mutation (gene change) in the affected individual. Most individuals with Alexander disease have a new mutation. As the disease becomes better diagnosed, familial cases, in which the disease is passed from one generation to the next, are being increasingly recognized. The risk of transmitting the disorder from an affected parent to offspring is 50 percent for each pregnancy. The risk is the same for males and females.

GFAP is a component of Rosenthal fibers, but how the mutations produce Alexander disease is not known. The Rosenthal fibers usually accumulate throughout the surfaces of the brain (cerebral cortex), and in the lower regions of the brain (brainstem), and the spinal cord, and primarily appear under the innermost of the protective membranes (meninges) surrounding the brain and spinal cord (pia mater); under the lining of the fluid-filled cavities (ventricles) of the brain (subependymal regions); and around blood vessels (perivascular regions). Studies in mice indicate that the mutations act by producing a new, toxic effect, rather than by interfering with the normal function of GFAP. This toxic effect may be due to the presence of the Rosenthal fibers, or to their precursors. Astrocytes perform many critical functions in the CNS, and several of these are affected by the GFAP mutations, but the importance of these changes to the disease is not yet known.

No metabolic defect has been identified as a cause of Alexander disease. "Metabolism" refers to all the chemical processes in the body, including the breakdown of complex substances into simpler ones (catabolism), usually with the release of energy, and processes in which complex substances are built up from simpler ones (anabolism), usually resulting in energy consumption. Metabolic disorders are characterized by abnormal functioning of specific enzymes that catalyze the chemical reactions in the body.

Affected Populations

Alexander disease has been estimated to occur at a frequency of about 1 in 1 million births. No racial, ethnic, geographic, or sex preference has been observed, nor is any expected given the de novo nature of the mutations responsible for most cases. Although initially diagnosed primarily in young children, it is now being observed with similar frequency at all ages. Since the mutations are dominant, there is a 50% chance that the child of an affected adult will have the disease.

Standard Therapies


For many years a brain biopsy to determine the presence of Rosenthal fibers was required for diagnosis of Alexander disease. However, even this procedure can be ambiguous, because these aggregates are also found in certain other disorders, such as tumors of astrocytes. More recently, MRI criteria have been developed that have a high degree of accuracy for diagnosing typical Type I (early onset) disease. These criteria have been less useful for some of the Type II cases which have little or no white matter deficits, and instead only show atrophy of the brainstem, cerebellum or spinal cord. Accordingly, when making the diagnosis, more common diseases that have similar symptoms for which tests are available should first be ruled out. These include adrenoleukodystrophy, Canavan's disease, glutaricacidurias, Krabbe leukodystrophy, Leigh syndrome, metachromic leukodystrophy, Pelizaeus-Merzbacher and Tay-Sachs disease. Definitive diagnosis of Alexander disease can be provided by identification of one of the known GFAP mutations in the patient's DNA, which can be obtained from a blood sample or a swab of the inside cheek. DNA analysis is provided by several commercial and research laboratories. However, since no GFAP mutation has been found in about 5% of known cases, a negative result does not rule out the disease. Presently cases without a GFAP mutation can be definitively diagnosed only at autopsy by the presence of disseminated Rosenthal fibers.


Treatment is symptomatic and supportive. Genetic counseling may be of benefit for patients and their families. Fetal diagnosis is an option for a couple who have had a previously affected child.

Investigational Therapies

A few treatments have been performed on individual patients, but there have been no trials performed to determine if they are truly effective. Information on current clinical trials is posted on the Internet at All studies receiving U.S. Government funding, and some supported by private industry, are posted on this government web site.

For information about clinical trials being conducted at the NIH Clinical Center in Bethesda, MD, contact the NIH Patient Recruitment Office:

Tollfree: (800) 411-1222

TTY: (866) 411-1010


For information about clinical trials sponsored by private sources, contact:

For information about clinical trials conducted in Europe, contact:

Current research on Alexander disease is focused on identifying the genetic change in all cases and investigating the mechanism of how the mutations lead to the disease. Also, being investigated is the exact composition of the Rosenthal fibers and the factors responsible for their formation and growth. Research is also underway to try to find ways to prevent the mutant GFAP from being made. Together, these studies may eventually lead to new methods of diagnosis and, in time, to the development of new treatments for Alexander disease.

Families and individuals wanting to participate in studies on Alexander disease should contact the United Leukodystrophy Foundation (ULF), (800) 728-5483.

Contact for additional information about Alexander Disease:

Albee Messing, VMD PhD

Professor of Neuropathology

Waisman Center on Mental Retardation

& Human Development and Department of Comparative Biosciences

University of Wisconsin-Madison

1500 Highland Avenue, Rm. 713

Madison, WI 53705-2280

Tel: (608) 263-9191 (office)

Cell Phone: 608-469-7315

Fax: (608) 263-4364

E-mail: MESSING@Waisman.Wisc.Edu



Messing, A, and Brenner, M. Alexander Disease and Astrotherapeutics, In Pathological potential of neuroglia: Possible new targets for medical intervention, eds. V Parpura, A Verkhratsky, in press. Springer, New York; 2014.

Flint, D and Brenner, M. Alexander disease, In Leukodystrophies. Raymond, G.V., Eichler, F., Fatemi, A., and Naidu, S., Mac Keith Press, London; 2011:106-129.

Brenner M, Goldman JE, Quinlan RA, Messing A. Alexander disease: a genetic disorder of astrocytes. In Astrocytes in Pathophysiology of the Nervous System, eds. V Parpura, PG Haydon, pp. 591-648. Boston: Springer; 2009:591-648.

Adams RD, et al., eds. Principles of Neurology. 6th ed. New York, NY: McGraw-Hill Companies, Inc.; 1997:945.

Behrman RE, et al., eds. Nelson Textbook of Pediatrics. 15th ed. Philadelphia, PA: W.B. Saunders Company; 1996:1727.


Prust M, et al. GFAP mutations, age at onset, and clinical subtypes in Alexander disease. Neurology 2011;77:1287-1294.

Yoshida T, et al. Nationwide survey of Alexander disease in Japan and proposed new guidelines for diagnosis. J Neurol 2011;258:1998-2008.

Hagemann TL., et al. Alexander disease-associated glial fibrillary acidic protein mutations in mice induce Rosenthal fiber formation and a white matter stress response. J Neurosci 2006;26:11162-11173.

Li, R, et al. Propensity for paternal inheritance of de novo mutations in Alexander disease. Hum. Genet. 2006;119:137-144.

Van der Knaap MS, et al. Alexander disease: ventricular garlands and abnormalities of the medulla and spinal cord. Neurology 2006;66:494-498.

Li R, et al. GFAP mutations in infantile, juvenile and adult forms of Alexander disease. Annals Neurol. 2005;57:310-326.

Van der Knaap MS, et al. Unusual variants of Alexander disease. Annals Neurol. 2005;57:327-338.

Brenner M, et al. Mutations in GFAP, encoding glial fibrillary acidic protein, are associated with Alexander disease. Nature Genetics 2001; 27:117-120.

Van der Knaap MS, et al. Alexander disease: diagnosis with MR imaging. Am. J. Neuroradiol. 2001;22:541-552.

Borrett D. Alexander's disease. Brain. 1985;108:367-385.

Alexander WS. Progressive fibrinoid degeneration of fibrillary astrocytes associated with mental retardation in a hydrocephalic infant. Brain. 1949;72:373-381.


Alexander Disease Website. Waisman Center, University of Wisconsin-Madison. Updated March 27, 2013.Available at: Accessed Feb 12, 2014.

Online Mendelian Inheritance in Man (OMIM). The Johns Hopkins University. Alexander Disease. Entry No: 203450. Last Edited March 15, 2013. Available at: Accessed Feb 12, 2014.


March of Dimes Birth Defects Foundation

1275 Mamaroneck Avenue

White Plains, NY 10605

Tel: (914)997-4488

Fax: (914)997-4763


United Leukodystrophy Foundation

224 N. 2nd St.

Suite 2

DeKalb, IL 60115

Tel: (815)748-3211

Tel: (800)728-5483



ELA - European Association Against Leukodystrophies

2, rue Mi-les-Vignes


Laxou Cedex, 61024


Tel: 33383309334

Fax: 33383300068



NIH/National Institute of Neurological Disorders and Stroke

P.O. Box 5801

Bethesda, MD 20824

Tel: (301)496-5751

Fax: (301)402-2186

Tel: (800)352-9424

TDD: (301)468-5981


Genetic and Rare Diseases (GARD) Information Center

PO Box 8126

Gaithersburg, MD 20898-8126

Tel: (301)251-4925

Fax: (301)251-4911

Tel: (888)205-2311

TDD: (888)205-3223


Madisons Foundation

PO Box 241956

Los Angeles, CA 90024

Tel: (310)264-0826

Fax: (310)264-4766



For a Complete Report

This is an abstract of a report from the National Organization for Rare Disorders, Inc.® (NORD). Cigna members can access the complete report by logging into For non-Cigna members, a copy of the complete report can be obtained for a small fee by visiting the NORD website. The complete report contains additional information including symptoms, causes, affected population, related disorders, standard and investigational treatments (if available), and references from medical literature. For a full-text version of this topic, see